AstraZeneca acquires Pearl Therapeutics
The deal provides access to a lucrative respiratory drug market as the company seeks to rebuild its pipeline.
The acquisition of the U.S. based respiratory drug specialist Pearl gives AstraZeneca a foothold in the newest area for lung treatments known as the LABA/LAMA class.
Already being developed by GlaxoSmithKline (GSK) and Novartis (NVS), these drugs are considered the exciting drug class of the future for treating Chronic Obstructive Pulmonary Disease or COPD, a disease that causes debilitating breathing problems in patients.
This new class of drugs works longer and is more effective in controlling the disease, with greatly improved patient compliance.
Pearl's PT003, a LABA/LAMA drug, is in final Stage III trials but may be late to the market according to some pharma analysts. Novartis is likely to gain first regulatory approval in Europe this year with GlaxoSmithKline next in line.
What might be more promising, and why AstraZeneca may be interested, is Pearl's PT010 drug that combines the LAMA and LABA components with an inhaled corticosteroid. It's only in Phase I trials currently but it could be accelerated to Phase II rapidly.
Still, it's not likely that AstraZeneca would be first to the market with this drug either. GlaxoSmithKline will likely gain approval for a similar drug first but being second in line is much better than being third.
AstraZeneca said that it would pay $560 million upfront plus up to $450 million if certain development criteria are achieved. It will also make sale-related payments of up to $140 million.
The company, once a dominant player in the pharma space, has lost ground as its aging pipeline loses patent protection. The company needs a new stock of drugs to replace big sellers like antipsychotic drug, Seroquel that went off-patent in 2012.
In May, AstraZeneca purchased Omthera Pharmaceuticals for as much as $443 million to strengthen its cardiovascular business. These acquisitions are an important part of new CEO Pascal Soriot as he answers the criticisms of shareholders who are calling for a pipeline rebuild.
The acquisition should close in the third quarter of 2013 and will have no impact on AstraZeneca’s guidance for the year, according to the drug maker.
More from Benzinga
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
These hot movers could rise by double digits in coming months.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.